Zynerba Pharmaceuticals closed at $13.52 in the latest trading session, marking a +0.15% move from the prior day. This change outpaced the S&P 500's 0.2% loss on the day. Elsewhere, the Dow lost 0.17%, while the tech-heavy Nasdaq lost 0.38%.
Prior to today's trading, shares of the specialty pharmaceutical company had gained 2.12% over the past month. This has outpaced the Medical sector's gain of 1.65% and the S&P 500's gain of 0.33% in that time.
Investors will be hoping for strength from ZYNE as it approaches its next earnings release. In that report, analysts expect ZYNE to post earnings of -$0.50 per share. This would mark year-over-year growth of 43.82%.
Any recent changes to analyst estimates for ZYNE should also be noted by investors. These revisions help to show the ever-changing nature of near-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. The Zacks Consensus EPS estimate has moved 1.83% higher within the past month. ZYNE is currently a Zacks Rank #3 (Hold).
The Medical - Generic Drugs industry is part of the Medical sector. This group has a Zacks Industry Rank of 180, putting it in the bottom 30% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.
Image: Bigstock
Zynerba Pharmaceuticals (ZYNE) Gains As Market Dips: What You Should Know
Zynerba Pharmaceuticals closed at $13.52 in the latest trading session, marking a +0.15% move from the prior day. This change outpaced the S&P 500's 0.2% loss on the day. Elsewhere, the Dow lost 0.17%, while the tech-heavy Nasdaq lost 0.38%.
Prior to today's trading, shares of the specialty pharmaceutical company had gained 2.12% over the past month. This has outpaced the Medical sector's gain of 1.65% and the S&P 500's gain of 0.33% in that time.
Investors will be hoping for strength from ZYNE as it approaches its next earnings release. In that report, analysts expect ZYNE to post earnings of -$0.50 per share. This would mark year-over-year growth of 43.82%.
Any recent changes to analyst estimates for ZYNE should also be noted by investors. These revisions help to show the ever-changing nature of near-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. The Zacks Consensus EPS estimate has moved 1.83% higher within the past month. ZYNE is currently a Zacks Rank #3 (Hold).
The Medical - Generic Drugs industry is part of the Medical sector. This group has a Zacks Industry Rank of 180, putting it in the bottom 30% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.